These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22581215)

  • 1. A tumor-derived population (SCCOHT-1) as cellular model for a small cell ovarian carcinoma of the hypercalcemic type.
    Otte A; Göhring G; Steinemann D; Schlegelberger B; Groos S; Länger F; Kreipe HH; Schambach A; Neumann T; Hillemanns P; Park-Simon TW; Hass R
    Int J Oncol; 2012 Aug; 41(2):765-75. PubMed ID: 22581215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
    Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
    Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
    Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line.
    Walt H; Hornung R; Fink D; Dobler-Girdziunaite D; Stallmach T; Spycher MA; Maly F; Haller U; Bürki N
    Anticancer Res; 2001; 21(5):3253-9. PubMed ID: 11848480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.
    Harrison ML; Hoskins P; du Bois A; Quinn M; Rustin GJ; Ledermann JA; Baron-Hay S; Friedlander ML
    Gynecol Oncol; 2006 Feb; 100(2):233-8. PubMed ID: 16321429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
    Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
    Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
    Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases.
    Callegaro-Filho D; Gershenson DM; Nick AM; Munsell MF; Ramirez PT; Eifel PJ; Euscher ED; Marques RM; Nicolau SM; Schmeler KM
    Gynecol Oncol; 2016 Jan; 140(1):53-7. PubMed ID: 26546963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
    Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
    J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of Ca²⁺ with the proliferation of SCCOHT-1 and ovarian adenocarcinoma cells.
    Otte A; Rauprich F; von der Ohe J; Hillemanns P; Hass R
    Int J Oncol; 2014 Sep; 45(3):1151-8. PubMed ID: 24969518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
    Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small cell carcinoma of the ovary of hypercalcemic type: a case report.
    McDonald JM; Karabakhtsian RG; Pierce HH; Iocono JA; Desimone CP; Bayliff SL; Ueland FR
    J Pediatr Surg; 2012 Mar; 47(3):588-92. PubMed ID: 22424359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.
    Otte A; Rauprich F; Hillemanns P; Park-Simon TW; von der Ohe J; Hass R
    Orphanet J Rare Dis; 2014 Aug; 9():126. PubMed ID: 25103190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
    Wang L; Tan C; Tu X; Zhang Y; Li X; Chang B
    Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-Cell Carcinoma of the Ovary of Hypercalcemic Type (Malignant Rhabdoid Tumor of the Ovary): A Review with Recent Developments on Pathogenesis.
    Witkowski L; Goudie C; Foulkes WD; McCluggage WG
    Surg Pathol Clin; 2016 Jun; 9(2):215-26. PubMed ID: 27241105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
    Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
    Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
    Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
    Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Wang Y; Chen SY; Colborne S; Lambert G; Shin CY; Santos ND; Orlando KA; Lang JD; Hendricks WPD; Bally MB; Karnezis AN; Hass R; Underhill TM; Morin GB; Trent JM; Weissman BE; Huntsman DG
    Mol Cancer Ther; 2018 Dec; 17(12):2767-2779. PubMed ID: 30232145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
    Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
    Chiriva-Internati M; Grizzi F; Weidanz JA; Ferrari R; Yuefei Y; Velez B; Shearer MH; Lowe DB; Frezza EE; Cobos E; Kast WM; Kennedy RC
    J Immunol Methods; 2007 Apr; 321(1-2):86-93. PubMed ID: 17336323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.